Patents Examined by Daniel E. Kolker
  • Therapeutic peptides for excitatory neurotoxicity-related injuries
    Patent number: 11229675
    Abstract: There is provided in the present application a peptide comprising the amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof. The peptide is an active peptide for the treatment of a central nervous system injury. The present application also provides a chimeric peptide comprising an active peptide and an internalization peptide. The present application also provides a pharmaceutical composition comprising the active peptide or the chimeric peptide, as well as medical use of the active peptide or the chimeric peptide.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: January 25, 2022
    Assignee: Biocells (Beijing) Biotech Co., Ltd.
    Inventors: Ying Lu, Huamin Han
  • Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as
    Patent number: 11225667
    Abstract: Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: January 18, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: Danielle Marie Mitchell, Leon F. Garcia-Martinez, Patricia Dianne McNeill, Ethan Wayne Ojala, Mehmet Inan, John Latham
  • Immunoglobulin-binding polypeptide
    Patent number: 11208441
    Abstract: An object of the present invention is to provide a polypeptide having a high binding capacity for an immunoglobulin kappa chain, and having excellent alkali stability, by modifying an amino acid sequence of an immunoglobulin-binding domain of Protein L derived from Peptostreptococcus magnus. A polypeptide having a high binding capacity for an immunoglobulin kappa chain, and having excellent alkali stability can be obtained by substituting specific lysine residues in an immunoglobulin-binding domain of Protein L derived from Peptostreptococcus magnus 3316 strain, with a basic amino acid or a hydroxyl group-containing amino acid.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: December 28, 2021
    Assignee: PROTENOVA CO., LTD.
    Inventors: Eiji Majima, Atsushi Shima
  • Anti-CD3 epsilon antibodies and methods of use thereof
    Patent number: 11203646
    Abstract: The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD3 epsilon (CD3?), as well as methods of making and using these anti-CD3? antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: December 21, 2021
    Assignee: NovImmune SA
    Inventors: Nicolas Fischer, Giovanni Magistrelli, Franck Gueneau, Ulla Ravn
  • Removal of leaked affinity purification ligand
    Patent number: 11192919
    Abstract: The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: December 7, 2021
    Assignee: AMGEN INC.
    Inventors: Samuel Ray Trejo, Robert Perry Brake
  • Chimeric antigen receptor
    Patent number: 11180553
    Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds human CD22, having an antigen-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—NYWIH (SEQ ID No. 1); CDR2—GINPGNNYATYRRKFQG (SEQ ID No. 2) CDR3—EGYGNYGAWFAY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—RSSQSLANSYGNTFLS (SEQ ID No. 4); CDR2—GISNRFS (SEQ ID No. 5) CDR3—LQGTHQPYT (SEQ ID No. 6). The present invention also provides a cell comprising such a CAR and the use of such a cell to treat cancer.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 23, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Shimobi Onuoha, Martin Pulé, Simon Thomas, Shaun Cordoba, Evangelia Kokalaki
  • Antibodies to royalactin and uses thereof
    Patent number: 11180536
    Abstract: Antibodies specific for royalactin (RA) can be used in methods for purifying royalactin, including native royalactin. These methods produce can produce compositions enriched for native royalactin. The purified royalactin can be used to produce cosmetic products that include native royalactin. An isolated nucleic acid encodes a monoclonal antibody that binds specifically to royalactin.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 23, 2021
    Assignee: WYL SCIENCES INC.
    Inventors: George P. Yang, Kevin C. Wang, Derrick C. Wan
  • BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof
    Patent number: 11161908
    Abstract: Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R). The CAR targeted to BAFF-R (BAFF-R CAR) described herein includes a domain that binds BAFF-R. Methods of making and using the BAFF-R CAR are also provided.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 2, 2021
    Assignees: City of Hope, Board of Regents, The University of Texas System
    Inventors: Hong Qin, Larry W. Kwak
  • Method to produce an immunoglobulin preparation with improved yield
    Patent number: 11136350
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 5, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Separating agent for human serum-derived IgG polyclonal antibodies, and method for separating human serum-derived IgG polyclonal antibodies using same
    Patent number: 11136609
    Abstract: An object of the present invention is to provide a separation agent for separating a human serum-derived IgG polyclonal antibody. This object is achieved by a separation agent for separating a human serum-derived IgG polyclonal antibody, the separation agent including: a carrier; and a single-chain antibody which has a dissociation constant for a human serum-derived IgG polyclonal antibody of not more than 3.0×10?8 M and which binds to the surface of the carrier via a chemical bond.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 5, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATION
    Inventors: Yoichi Kumada, Yuya Hasegawa, Seiichi Uchimura
  • Nato3 mutant polypeptides and uses thereof
    Patent number: 11111279
    Abstract: The present invention relates to isolated Nato3 mutant polypeptides. Methods for stimulating a brain cell to differentiate into a dopaminergic progenitor neuronal cell or a dopaminergic neuron comprises increasing phosphorylation of Nato3 in the brain cells and culturing the brain cells until a progenitor dopaminergic neuronal cell marker or a dopaminergic neuronal cell marker is expressed in the cultured brain cells. Methods for treating Parkinson's disease (PD) in a subject comprises administering to the subject in need thereof, a composition comprising progenitor dopaminergic neuronal cells and/or dopaminergic neuronal cells expressing a Nato3 mutant polypeptide to the brain of the subject.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: September 7, 2021
    Assignee: GRAND VALLEY STATE UNIVERSITY
    Inventors: Merritt DeLano-Taylor, Jordan Straight, Doug Peterson, Nick Huisingh, Daniel Doyle
  • Hydrophobic interaction protein chromatography under no-salt conditions
    Patent number: 11111269
    Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: September 7, 2021
    Assignee: Biogen MA Inc.
    Inventors: Sanchayita Ghose, Yinying Tao
  • Charged depth filtration of antigen-binding proteins
    Patent number: 11098079
    Abstract: Methods of producing an aqueous formulation of an antigen-binding protein or enhancing re-oxidation of an antigen-binding protein are disclosed. The methods comprise (a) contacting an aqueous solution comprising antigen-binding protein molecules with a charged depth filter under conditions sufficient to enhance re-oxidation of the antigen-binding protein molecules and achieve a decrease in the percentage of reduced antigen-binding protein molecules, compared to the percentage of reduced antigen-binding protein molecules observed prior to step (a); and (b) optionally, measuring the amount or relative amount of reduced antigen-binding protein molecules. Formulations comprising a re-oxidized antigen-binding protein are also described.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 24, 2021
    Assignee: AMGEN INC.
    Inventors: Hai Hoang, Rafael Gonzalez, Junfen Ma
  • Caustic stable chromatography ligands
    Patent number: 11084851
    Abstract: The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 10, 2021
    Assignee: EMD MILLIPORE CORPORATION
    Inventors: Nanying Bian, Neil Soice, Shari Spector, Kara Levine
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11085935
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 10, 2021
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Single chain intrabodies that alter Huntingtin mutant degradation
    Patent number: 11072650
    Abstract: Compositions and methods of use are provided for intrabodies that bind and alter the effects of poly-glutamate protein aggregation in poly-glutamate associated diseases, such as in Huntington's disease. Intrabodies are provided that prevent poly-glutamate aggregation, gene dysregulation, and negative effects of Huntington's disease.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: July 27, 2021
    Assignee: Vybion, Inc.
    Inventors: Lee Alan Henderson, Irene Alexandra Amaro
  • Peptides having effects of preventing or treating central nervous system diseases and pharmaceutical compositions for preventing or treating central nervous system diseases containing same as active ingredient
    Patent number: 11053295
    Abstract: The present invention has a function of enabling the penetration of the blood-brain barrier and the blood-spinal cord barrier of the central nervous system, which have not been significantly penetrated, with excellent efficiency, thereby enabling a rapid, quick, and more efficient therapeutic effect to be obtained through low dose administration. In addition, the present invention enables local administration unlike conventional therapeutic agents, thereby decreasing side effects, and enables local administration of a therapeutic agent at a high concentration, thereby enabling potentially new treatments and prescriptions.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 6, 2021
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Je-Min Choi, Sangho Lim
  • Method for the purification of antibodies
    Patent number: 11034754
    Abstract: A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: June 15, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Burkard Kolb, Maria Sebald
  • Chimeric antigen receptor that binds HLA-DR and CAR-T cell
    Patent number: 11013765
    Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: May 25, 2021
    Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
  • De novo binding domain containing polypeptides and uses thereof
    Patent number: 11008397
    Abstract: Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: May 18, 2021
    Assignees: Subdomain, LLC, Arcellx, Inc.
    Inventors: David William Lafleur, David M. Hilbert